76 survived (21.6% were in mTOR-I) and 28 died (3.9% were in mTOR-I)57 pts developed ARDS (20% were in mTOR-I) 47 pts did not develop ARDS (31.9% were in mTOR-I)No relationship between type of immunosuppression modification and mortality. The gene discussed is MTOR; the disease is acute respiratory distress syndrome.